The clinical trial for [123I] MNI-308, sponsored by Molecular NeuroImaging, aimed to evaluate its efficacy as an imaging biomarker for beta-amyloid burden in Alzheimer's disease (AD) patients compared to healthy controls. The termination of the trial due to preliminary data indicating that [123I] MNI-308 is not a useful tool for detecting AD suggests significant challenges in the market for imaging agents targeting amyloid deposition. This outcome may limit the commercial viability of [123I] MNI-308 and reflects broader competitive pressures in the neuroimaging market, particularly as other imaging modalities and biomarkers are being explored. Stakeholders should consider the implications of this termination for future investment and development strategies in neurodegenerative disease diagnostics.